• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CIRSE 2017 Round-up: Delcath touts second-gen hemofiltration system in percutaneous hepatic perfusion

September 19, 2017 By Sarah Faulkner

Boston Scientific touts 3-year data for Eluvia paclitaxel-eluting vascular stent

Boston ScientificBoston Scientific (NYSE:BSX) touted three-year results from the Majestic trial of its Eluvia paclitaxel-eluting vascular stent system yesterday at CIRSE.

The trial, which enrolled 57 patients with symptomatic lower limb ischemia and lesions in the superficial femoral artery or proximal popliteal artery, had a primary patency rate of 83.5% through two years.

After three years, 85.3% of patients were experiencing freedom from target lesion revascularization, the company reported.

“Over the course of the Majestic trial, the majority of the patients, including those with relatively challenging lesions, have remained largely symptom-free,” principal investigator Dr. Stefan Müller-Hülsbeck said in prepared remarks. “The sustained drug release enabled by the polymer-based stent can be credited with reduced reinterventions over a three-year period, as well as establishing a long-term safety profile in the femoropopliteal arteries.”

Boston Scientific also recently finished enrolling 485 patients in the head-to-head Imperial trial, which is slated to compare the Eluvia stent system to Cook Medical’s Zilver PTX stent. Initial results, which Boston Scientific anticipates it will have by next year, will be used to support regulatory submissions for Eluvia in the U.S. and Japan.

“It is reassuring to see the demonstrated long-term durability of the Eluvia Stent System and we look forward to continuing to expand the clinical knowledge within the peripheral application of drug-eluting technologies,” Jeff Mirviss, president of Peripheral Interventions at Boston Scientific, added. “We are fully committed to advancing therapies that can benefit patients suffering from lower limb ischemia, a group that is often times lacking successful treatment options that help avoid the possibility of experiencing amputations.”

The Eluvia stent won CE Mark clearance in February last year.

Pages: Page 1 Page 2 Page 3

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Biotronik, Boston Scientific, Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS